Week of September 28st, 2020 | Vol. 9, Issue 39
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Aspen
Sell-side | Pharma Services | Multi-national contract manufacturing and packaging organization

Project Athena
Sell-side | Medical Device | Novel medical device for the treatment of pelvic organ prolapse

Project Vista
Out-partnering | Pharma | Seeking commercial partner for novel, liquid-format riluzole treatment of ALS

Project Seal
Buy-side | Pharma | Seeking Pain and CNS products as well as legacy/tail commercial pharma assets

Project Olympus
Sell-side | Pharma | Portfolio of generic injectable products
American Injectables Inc., a sterile injectables manufacturing company located near Tampa Bay, FL, secured a commitment for $10 million of Series A financing from New Rhein Healthcare Investors. The company will use the funds to scale its production and launch several parenteral products in order to work toward alleviating current drug shortages in the US and address the high unmet need for sterile injectables. The company’s strategy is also responsive to the US Government’s August 6, 2020 executive order supporting US-based manufacture of essential medicines.

American Injectables’ newly constructed facility includes state-of-the-art equipment and an integrated third-party analytical lab. It has a currently installed manufacturing capacity of 16 million units with expansion capability up to 50 million units.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
18 transactions totaling $9,560 million
Supplies, Equipment & Services
22 transactions totaling $376 million
Healthcare IT & Managed Care
2 transactions totaling $4 million
Healthcare Facilities & Distributors
16 transactions totaling $267 million
Pharma & Biotech
24 transactions totaling $506 million
Supplies, Equipment & Services
18 transactions totaling $225 million
Healthcare IT & Managed Care
11 transactions totaling $168 million
Healthcare Facilities & Distributors
1 transaction
Pharma & Biotech
28 transactions totaling $8,521 million
Supplies, Equipment & Services
10 transactions totaling $1,857 million
Healthcare IT & Managed Care
1 transaction totaling $2,200
Healthcare Facilities & Distributors
1 transaction totaling $49 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
September 25, 2020 - Fierce Biotech
As of June 30, the company said it owed about $138.9 million in a combined principal amount of outstanding debts. Total revenue for 2018 and 2019 topped $90.8 million and $95.9 million, respectively, for a growth rate of about 5.7%. But over the first six months of 2020, the company brought in $42.7 million, a decrease of about 7.3% compared to the same period the year before, largely due to delays in elective surgical procedures caused by the COVID-19 pandemic. 

September 24, 2020 - Contract Pharma
Catalent, a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, has acquired a new manufacturing facility in Bloomington, IN, to create a North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services. The $14 million investment includes the acquisition, build-out, and qualification of the facility to begin supporting customer programs starting January 2021.

September 22, 2020 - Fierce Pharma
AstraZeneca tapped Samsung Biologics for a $331 million supply pact to produce bulk drug substance and "drug product to support AstraZeneca's biologics therapeutics" at the CMO's Plant 3 facility in Incheon, South Korea, the partners said Tuesday.

September 22, 2020 - Fierce Biotech
Johnson & Johnson has begun a 60,000-subject phase 3 assessment of its COVID-19 vaccine. The trial will enroll participants in the U.S. and other countries with a high incidence of COVID-19 with a view to generating data to support emergency use authorization early next year.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.